Skip to main content

SIBN

Stock
Health Care
Medical Devices

Performance overview

SIBN Price
Price Chart

Forward-looking statistics

Beta
1.31
Risk
55.51%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Company info

SectorHealth Care
IndustryMedical Devices
Employees422
Market cap$547.2M

Fundamentals

Enterprise value$694.7M
Revenue$176.6M
Revenue per employee—
Profit margin-15.03%
Debt to equity22.21

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.63
Dividend per share—
Revenue per share$4.22
Avg trading volume (30 day)$8M
Avg trading volume (10 day)$9M
Put-call ratio—

Macro factor sensitivity

Growth+0.8
Credit+2.7
Liquidity-0.1
Inflation-1.5
Commodities-0.5
Interest Rates-2.8

Valuation

Dividend yield0.00%
PEG Ratio-24.63
Price to sales4.46
P/E Ratio-24.63
Enterprise Value to Revenue3.93
Price to book4.69

Upcoming events

Next earnings dayNovember 10, 2025
Next dividend day—
Ex. dividend day—

News

All You Need to Know About Si-Bone (SIBN) Rating Upgrade to Buy

Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (July 7, 2025)
Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research (May 26, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free